Forecasted · Grant
Functional Target Validation for Alzheimer's Disease-Related Dementias
National Institutes of Health, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Functional Target Validation for Alzheimer's Disease-Related Dementias
- Issuing agency
- National Institutes of Health (Department of Health and Human Services)
- Opportunity number
- RFA-NS-26-034
- Funding type
- Grant
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close November 6, 2026 (agency estimate)
- Agency estimates
- Estimated posting: May 5, 2026. Estimated award date: June 14, 2027. Estimates can change.
- Published award range
- Not published by the agency
- Estimated total program funding
- $1,800,000
- Expected number of awards
- 2
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.853
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/361450 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 361450 · Funding opportunity number RFA-NS-26-034
- Posted
- March 11, 2026 · Source last updated March 11, 2026
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 92% of key fields published by the sourceNot published: published funding range.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Eligibility details (from the agency)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions) are not allowed
Description (from the official listing)
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting ambitious research projects that propose comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease–Related Dementias (ADRD). A major barrier to the development of effective treatments for ADRD, as well as other complex central nervous system disorders, is the lack of well-validated targets that are clearly linked to disease mechanisms. Successful translation of basic discoveries into the clinic depends on the rigor of target validation and confidence in a causal relationship between modulation of a target and its functional physiological consequences relevant to treating or preventing disease. This initiative aims to de-risk subsequent translational research and accelerate the development of novel therapeutic strategies.NINDS believes that this initiative would be most appropriately supported by a phased award mechanism (for example, R61/R33). In the initial phase, support would be provided for the development of customized technologies, models, and protocols to modulate the expression or activity of candidate targets and to assess their physiological consequences in relevant in vitro and in vivo disease models. Upon successful achievement of predefined, milestone-based technical feasibility and proof-of-concept criteria, projects would transition to the second phase focused on measuring and cross-validating the effects of target modulation across multiple experimental modalities and collaborating laboratories, in accordance…
Read the full description
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting ambitious research projects that propose comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease–Related Dementias (ADRD). A major barrier to the development of effective treatments for ADRD, as well as other complex central nervous system disorders, is the lack of well-validated targets that are clearly linked to disease mechanisms. Successful translation of basic discoveries into the clinic depends on the rigor of target validation and confidence in a causal relationship between modulation of a target and its functional physiological consequences relevant to treating or preventing disease. This initiative aims to de-risk subsequent translational research and accelerate the development of novel therapeutic strategies.NINDS believes that this initiative would be most appropriately supported by a phased award mechanism (for example, R61/R33). In the initial phase, support would be provided for the development of customized technologies, models, and protocols to modulate the expression or activity of candidate targets and to assess their physiological consequences in relevant in vitro and in vivo disease models. Upon successful achievement of predefined, milestone-based technical feasibility and proof-of-concept criteria, projects would transition to the second phase focused on measuring and cross-validating the effects of target modulation across multiple experimental modalities and collaborating laboratories, in accordance with NIH rigor and reproducibility guidelines.Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop responsive projects and establish appropriate cross-disciplinary collaborations.
Agency contact
NINDS DTR ADRD
NINDSDTRADRD@mail.nih.gov